National Health (Highly Specialised Drugs Program) Special Arrangement Amendment (January Update) Instrument 2021 (Cth)

PB 131 of 2021

National Health (Highly Specialised Drugs Program) Special Arrangement Amendment (January Update) Instrument 2021

National Health Act 1953

I, NIKOLAI TSYGANOV, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 100(2) of the National Health Act 1953.

Date                 22 December 2021

NIKOLAI TSYGANOV

Assistant Secretary (Acting)

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

________________________________________________________________________

Contents

1......... Name............................................................................................................................... 1

2......... Commencement............................................................................................................... 1

3......... Authority......................................................................................................................... 1

4......... Schedules......................................................................................................................... 1

Schedule 1—Amendments  2

National Health (Highly Specialised Drugs Program) Special Arrangement 2021
(PB 27 of 2021)   2

1. Name

(1)This instrument is the National Health (Highly Specialised Drugs Program) Special Arrangement Amendment (January Update) Instrument 2021.

(2)This instrument may also be cited as PB 131 of 2021.

1. Commencement

(1)Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1.  The whole of this instrument	1 January 2022	1 January 2022

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

1. Authority

This instrument is made under subsection 100(2) of the National Health Act 1953.

1. Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Highly Specialised Drugs Program) Special Arrangement 2021 (PB 27 of 2021)

1. Subsection 17(3)

omit: 1 January 2022          insert: 1 July 2022

1. Schedule 1, Part 1, entry for Deferasirox in the form Tablet 90 mg [Maximum Quantity: 180; Number of Repeats: 2]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Deferasirox Sandoz C7374 C7375 C7385 C8326 C8328 C8329 C9222 C9258 C9302 P7385 P8326 P8328 P8329 P9222 P9258 P9302 180 2

1. Schedule 1, Part 1, entry for Deferasirox in the form Tablet 90 mg [Maximum Quantity: 180; Number of Repeats: 5]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Deferasirox Sandoz C7374 C7375 C7385 C8326 C8328 C8329 C9222 C9258 C9302 P7374 P7375 180 5

1. Schedule 1, Part 1, entry for Deferasirox in the form Tablet 180 mg [Maximum Quantity: 180; Number of Repeats: 2]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Deferasirox Sandoz C7374 C7375 C7385 C8326 C8328 C8329 C9222 C9258 C9302 P7385 P8326 P8328 P8329 P9222 P9258 P9302 180 2

1. Schedule 1, Part 1, entry for Deferasirox in the form Tablet 180 mg [Maximum Quantity: 180; Number of Repeats: 5]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Deferasirox Sandoz C7374 C7375 C7385 C8326 C8328 C8329 C9222 C9258 C9302 P7374 P7375 180 5

1. Schedule 1, Part 1, entry for Deferasirox in the form Tablet 360 mg [Maximum Quantity: 180; Number of Repeats: 2]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Deferasirox Sandoz C7374 C7375 C7385 C8326 C8328 C8329 C9222 C9258 C9302 P7385 P8326 P8328 P8329 P9222 P9258 P9302 180 2

1. Schedule 1, Part 1, entry for Deferasirox in the form Tablet 360 mg [Maximum Quantity: 180; Number of Repeats: 5]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Deferasirox Sandoz C7374 C7375 C7385 C8326 C8328 C8329 C9222 C9258 C9302 P7374 P7375 180 5